AU762376C - Expression and characterization of HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response - Google Patents

Expression and characterization of HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response

Info

Publication number
AU762376C
AU762376C AU54642/99A AU5464299A AU762376C AU 762376 C AU762376 C AU 762376C AU 54642/99 A AU54642/99 A AU 54642/99A AU 5464299 A AU5464299 A AU 5464299A AU 762376 C AU762376 C AU 762376C
Authority
AU
Australia
Prior art keywords
hiv
proteins
dna
amino acid
neutralization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU54642/99A
Other languages
English (en)
Other versions
AU5464299A (en
AU762376B2 (en
Inventor
Gerald V. Quinnan Jr.
Peng Fei Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Publication of AU5464299A publication Critical patent/AU5464299A/en
Application granted granted Critical
Publication of AU762376B2 publication Critical patent/AU762376B2/en
Publication of AU762376C publication Critical patent/AU762376C/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AU54642/99A 1998-08-04 1999-08-04 Expression and characterization of HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response Ceased AU762376C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9526798P 1998-08-04 1998-08-04
US60/095267 1998-08-04
PCT/US1999/017596 WO2000007631A1 (en) 1998-08-04 1999-08-04 Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response

Publications (3)

Publication Number Publication Date
AU5464299A AU5464299A (en) 2000-02-28
AU762376B2 AU762376B2 (en) 2003-06-26
AU762376C true AU762376C (en) 2004-10-14

Family

ID=22251048

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54642/99A Ceased AU762376C (en) 1998-08-04 1999-08-04 Expression and characterization of HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response

Country Status (7)

Country Link
EP (1) EP1104310B1 (enExample)
JP (1) JP4637356B2 (enExample)
AT (1) ATE435034T1 (enExample)
AU (1) AU762376C (enExample)
CA (1) CA2338886C (enExample)
DE (1) DE69941051D1 (enExample)
WO (1) WO2000007631A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW511388B (en) 2000-03-28 2002-11-21 Koninkl Philips Electronics Nv Passive radiator having mass elements
CA2483870A1 (en) * 2002-05-10 2004-06-03 The Henry M. Jackson Foundation Interacting site for gp41 on gp120 of hiv-1
WO2004113370A1 (de) 2003-06-20 2004-12-29 Dade Behring Marburg Gmbh NEUE OBERFLÄCHENPROTEIN-(HBsAG-) VARIANTE DES HEPATITIS B VIRUS
ATE552264T1 (de) * 2003-06-20 2012-04-15 Siemens Healthcare Diagnostics Neue oberflächenprotein- (hbsag-) variante des hepatitis b virus
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
JP2009536653A (ja) * 2006-05-09 2009-10-15 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド Ｈｉｖ−１免疫原性組成物
US8597658B2 (en) * 2007-11-12 2013-12-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. HIV-1 envelope glycoprotein oligomer and methods of use
EP2552480A1 (en) 2010-03-26 2013-02-06 GlaxoSmithKline Biologicals S.A. Hiv vaccine
US20130280322A1 (en) 2010-09-27 2013-10-24 Glaxosmithkline Biologicals S.A. Vaccine
EP2892554B1 (en) 2012-09-07 2020-08-26 Emory University Hiv immune stimulating compositions comprising recombinantly expressed pili on bacteria and methods related thereto

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439809A (en) * 1989-10-13 1995-08-08 Connaught Laboratories Limited Non-infectious HIV particles lacking long terminal repeats
US5622933A (en) * 1993-09-13 1997-04-22 Armel S.A. Multiple branch peptide constructions for use against HIV
US5756674A (en) * 1992-05-14 1998-05-26 Herman Katinger Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820865A (en) * 1988-01-26 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method to induce cytotoxic T Lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides
EP0586505A1 (en) * 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439809A (en) * 1989-10-13 1995-08-08 Connaught Laboratories Limited Non-infectious HIV particles lacking long terminal repeats
US5756674A (en) * 1992-05-14 1998-05-26 Herman Katinger Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates
US5622933A (en) * 1993-09-13 1997-04-22 Armel S.A. Multiple branch peptide constructions for use against HIV

Also Published As

Publication number Publication date
EP1104310A1 (en) 2001-06-06
CA2338886C (en) 2011-10-04
ATE435034T1 (de) 2009-07-15
WO2000007631A9 (en) 2000-11-16
AU5464299A (en) 2000-02-28
DE69941051D1 (de) 2009-08-13
EP1104310B1 (en) 2009-07-01
EP1104310A4 (en) 2003-01-08
CA2338886A1 (en) 2000-02-17
WO2000007631A1 (en) 2000-02-17
AU762376B2 (en) 2003-06-26
JP2002522039A (ja) 2002-07-23
JP4637356B2 (ja) 2011-02-23

Similar Documents

Publication Publication Date Title
Bures et al. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
AU729231B2 (en) Synthetic HIV genes
AP1282A (en) HIV envelope polypeptides and vaccine.
US6585979B1 (en) HIV envelope polypeptides and immunogenic composition
AU762376C (en) Expression and characterization of HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response
US20100015211A1 (en) Combination Approaches For Generating Immune Responses
US20070166784A1 (en) Combination approaches for generating immune responses
US20100080818A1 (en) Expression and Characterization of HIV-1 Envelope Protein Associated with Broadly Cross Reactive Neutralizing Antibody Response
JP5290576B2 (ja) 修飾されたｈｉｖ−１エンベロープタンパク質
AU2003299489B2 (en) Interacting site for gp41 on gp120 of HIV-1
Jones-Trower Characterization and Enhanced Processing of Soluble, Oligomeric gp140 Envelope Glycoproteins Derived from Human Immunodeficiency Virus Type-1 Primary Isolates
US20030087225A1 (en) Synthetic HIV genes
ZA200603029B (en) Combination approaches for generating immune responses

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20031223

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE OFFICIAL JOURNAL DATED 20040422